CAPOX

From Wikipedia, the free encyclopedia
Jump to: navigation, search

CAPOX (also called XELOX[1]) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.[2][3]

Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is orally taken for twice daily for two weeks, while oxaliplatin is administrated by IV on the first day of the cycle; there is a one-week rest period before the next cycle.

Adverse effects[edit]

References[edit]

  1. ^ Cassidy, J.; Tabernero, J.; Twelves, C.; Brunet, R.; Butts, C.; Conroy, T.; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Schöffski, P.; Sobrero, A.; Van Cutsem, E.; Díaz-Rubio, E. (2004). "XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer". Journal of Clinical Oncology. 22 (11): 2084–2091. PMID 15169795. doi:10.1200/JCO.2004.11.069. 
  2. ^ Capecitabine Combined with Oxaliplatin (CapOx) in Clinical Practice: How Significant is Peripheral Neuropathy? D. J. Storey; M. Sakala; C. M. McLean; H. A. Phillips; L. K. Dawson; L. R. Wall; M. T. Fallon; S. Clive. Posted: 09/28/2010; Annals of Oncology. 2010;21(8):1657-1661. © 2010 Oxford University Press
  3. ^ Twelves C, Wong A, Nowacki MP, et al. (June 2005). "Capecitabine as adjuvant treatment for stage III colon cancer". N. Engl. J. Med. 352 (26): 2696–704. PMID 15987918. doi:10.1056/NEJMoa043116.